Dermatitis
13 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Abrocitinib for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amlitelimab for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATI-045 for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dupilumab for dermatitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dupilumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Lebrikizumab for dermatitis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lebrikizumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Optical Coherence Tomography + Reflectance confocal microscopy + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + LEBRIKIZUMAB for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Roflumilast for dermatitis, seborrheic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| TAR-0520 gel for hand-foot syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |